<DOC>
	<DOCNO>NCT02141763</DOCNO>
	<brief_summary>A study UCB4940 subject psoriatic arthritis evaluate safety body distribution UCB4940 patient . Neither patient doctor know treatment group .</brief_summary>
	<brief_title>Multiple Dose Study UCB4940 Subjects With Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Have diagnosis adultonset psoriatic arthritis make least 6 month prior Screening define Classification Criteria Psoriatic Arthritis Subject must active psoriatic lesion history psoriatic skin lesion Subject must active arthritis Subject inadequate response least 1 nonbiologic DiseaseModifying Antirheumatic Drug ( DMARD ) ( may include methotrexate [ MTX ] ) and/or 1 approve biologic DMARD Subject must take concurrent MTX least 3 month time Screening , stable dose least 4 week prior Baseline Female subject must postmenopausal ( least 1 year ) , permanently sterilize , childbearing potential , must willing use least 2 effective method contraception study period Subject clinical laboratory test result within reference range test laboratory Subject Electrocardiogram ( ECG ) value within reference range test laboratory Subject absolute neutrophil count &lt; 1.5×109/L , and/or lymphocyte count &lt; 1.0×109/L Subject know viral hepatitis , positive test hepatitis B surface antigen hepatitis C virus antibody positive Subject test positive human immunodeficiency virus ( HIV ) 1/2 antibody Subject past medical history family history primary immunodeficiency Subject splenectomized Subject severe infection require hospitalization and/or treatment iv antibiotic 6 month Screening Visit Subject history positive tuberculosis ( TB ) test evidence possible TB latent TB infection Screening Subject high risk acquire TB infection Subject history alcoholism drug/chemical abuse Subject active infection serious within 6 week first dose Investigational Medicinal Product ( IMP ) Subject renal liver impairment Screening Visit Subject active neoplastic disease history neoplastic disease within 5 year study entry ( except basal squamous cell carcinoma skin carcinoma situ definitively treat standard care approach consider cured Screening ) Subject acute chronic illness , opinion Investigator Study Physician , could pose threat harm subject Subjects must diagnosis inflammatory arthritis , eg , rheumatoid arthritis , sarcoidosis , systemic lupus erythematosus Subject current past history gastrointestinal ulceration Subjects must noninflammatory condition ( eg , osteoarthritis know diagnosis fibromyalgia ) Investigator 's opinion symptomatic enough interfere evaluation effect IMP subject 's primary diagnosis Psoriatic Arthritis ( PsA ) Subject receive live vaccination within 6 week Screening Visit intend need live vaccination course study 3 month follow last IMP dose Subject inadequate response 1 approve biologic DrugModifying Antirheumatic Drug ( DMARD ) Subject receive investigational drug experimental procedure within 90 day 5 halflives whichever longer first dose UCB4940</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
</DOC>